RHYTHM PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $6.05B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | Before market open | $71.30M | $-0.73 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | $60.10M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $57.30M | $-0.73 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | $51.30M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $48.50M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | – | $-0.81 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | Before market open | $41.80M | $-0.72 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | After market close | $33.30M | $-0.73 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | $29.10M | $-0.55 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | $26.00M | $-2.35 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | Before market open | $24.20M | $-0.70 | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| R&D expensesGAAP | year ending December 31, 2026 | $175.00M to $195.00M | Lowered |
| SG&A expensesGAAP | year ending December 31, 2026 | $188.00M to $202.00M | Raised |
| Non-GAAP Operating Expensesnon-GAAP | year ending December 31, 2026 | $363.00M to $397.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Rhythm Pharmaceuticals filed with the SEC
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
© Rhythm® Pharmaceuticals, Inc. All rights reserved. ® August 4, 2026 Rhythm Pharmaceuticals Second Quarter 2026 Financial Results and Business Update EXHIBIT 99.3
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
® © Rhythm® Pharmaceuticals, Inc. All rights reserved. June 13, 2026 Rhythm Pharmaceuticals Positive Interim Six-month Results from Phase 2 Trial Evaluating Setmelanotide in Patients with Prader-Willi Syndrome EXHIBIT 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Announces Changes to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE ® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE ® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© Rhythm® Pharmaceuticals, Inc. All rights reserved. ® March 19, 2026 Rhythm Pharmaceuticals IMCIVREE (Setmelanotide) FDA Approval in Acquired Hypothalamic Obesity EXHIBIT 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© Rhythm® Pharmaceuticals, Inc. All rights reserved. ® Rhythm Pharmaceuticals Phase 3 EMANATE Trial Topline Results March 16, 2026 EXHIBIT 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© Rhythm® Pharmaceuticals, Inc. All rights reserved. ® Rhythm Pharmaceuticals Corporate Presentation January 2026 EXHIBIT 99.2
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© Rhythm® Pharmaceuticals, Inc. All rights reserved.
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE ®
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© Rhythm® Pharmaceuticals, Inc. All rights reserved.
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Announces Oral MC4R Agonist
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
8 ® Overall Baseline Demographics N=28 46.4% Female 25.4yo Mean Age (13 of 28 <18yo) 38.7 kg/m 2 Mean BMI 82.1% Patients with craniopharyngioma 7 years Mean time from hypothalamic injury to trial enrollment Overall bivamelagon population
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© 2025. Rhythm Pharmaceuticals, Inc. All rights reserved.
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE ® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© Rhythm® Pharmaceuticals, Inc. All rights reserved.
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rhythm Pharmaceuticals Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Reports First Quarter 2024 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Secures $150 Million in Convertible Preferred Stock Financing
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Reports Fourth Quarter
Results of operations · Other events · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Rhythm Pharmaceuticals Reports First Quarter
Results of operations · EX-99.1 to Form 8-K